NCT03895879View on ClinicalTrials.gov

Use of Tocilizumab Drug Levels to Optimize Treatment in RA

PHASE4RecruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tocilizumab

Tocilizumab sc (162 mg) once every 2 weeks

DRUG

Tocilizumab

Tocilizumab sc (162 mg) once every week

Trial Locations (1)

1056 AB

RECRUITING

Reade Rheumatology Research Institute, Amsterdam

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Reade Rheumatology Research Institute

OTHER